Recommendation made by the extraordinary PBAC Meeting - November 2006

PDF Printable version this page (PDF 19 KB)

Recommendation made by the Pharmaceutical Benefits Advisory Committee (PBAC) at an extraordinary November 2006 meeting relating to the inclusion of Quadrivalent Human Papillomavirus recombinant vaccine in the National Immunisation Program (NIP)

Table containing positive recommendations for Insulin Glargine from May 2006 Extraordinary Meeting
Drug and Form Drug Use and Type Listing Requested by Sponsor PBAC Recommendation
Quadrivalent Human Papillomavirus recombinant vaccine, (Types 6, 11, 16, 18), injection, Gardasil®,
CSL Pharmaceuticals
Minor submission
Vaccine For inclusion on the National Immunisation Program for 12 year old girls and a catch-up program for all girls and women 13-26 years. The PBAC recommended that a school-based program (for 12 to 18 year-old girls) be implemented under the National Immunisation Program (NIP) on the basis of a high, but acceptable cost-effectiveness ratio resulting from a price reduction. Following further negotiations, the PBAC subsequently recommended funding of the 18-26 year cohort on the NIP, as a catch-up program for a period of 2 years.